Tissue Kallikrein 1 (KLK1) Therapeutics Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Tissue Kallikrein 1 (KLK1) Therapeutics Market in 2026?

USD 870.0 million in 2026 and USD 2,195.8 million by 2036 at a 9.7% CAGR.

KLK1 therapeutics demand is projected to reach USD 2,195.8 million by 2036 from USD 870.0 million in 2026 and is supported by recombinant development at a 9.7% CAGR. Revenue combines marketed kallidinogenase preparations in Asian countries with investigational recombinant KLK1 programs that remain outside commercial sales in Western markets. The commercial pathway therefore depends on clinical endpoints and scalable biologic production rather than one global launch model. DiaMedica’s March 2026 annual filing states that DM199 has no commercial approval and requires additional clinical testing before sales infrastructure becomes relevant. Sponsors using clinical trial services must coordinate enrollment evidence with dosing windows and regional ethics requirements across each active study network. Product developers using biologics contract manufacturing also need reliable active-substance supply that remains consistent through pivotal studies and registration batches.

Japanese clinicians can prescribe current kallidinogenase products while United States and United Kingdom centers use DM199 through controlled clinical research. Japan’s outlook is projected at 11.9% CAGR through 2036, supported by current product access and a separate recombinant registration route. The United States outlook is estimated at 7.8% CAGR during the assessment period and is shaped by pivotal outcomes plus partner-led commercialization planning. United Kingdom demand is forecast to expand at 7.4% CAGR between 2026 and 2036 and is enabled by NHS research participation plus later health-technology assessment. Companies comparing stroke aspiration systems with investigational KLK1 must distinguish thrombectomy workflows from patients who lack a qualifying intervention. Commercial entry requires formulation-specific evidence because oral animal-derived products cannot establish acceptance for recombinant injectable DM199.

Summary of the Tissue Kallikrein 1 (KLK1) Therapeutics Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Spending rises as developers and established Asian producers address vascular disorders through products with different evidence stages and commercial access. Recombinant programs require multicenter outcomes that justify regulatory review and support a credible reimbursement discussion across every intended indication. Marketed kallidinogenase products generate routine demand through national channels without proving equivalent acceptance for recombinant formulations in other countries. Distinct clinical endpoints and treatment settings create separate development economics for stroke and pregnancy programs across participating sites. Manufacturing continuity influences valuation because recombinant proteins need controlled expression systems and extracted preparations depend on stable biological raw materials.
Product and Segment View	The product architecture spans recombinant human KLK1 and marketed kallidinogenase preparations with different manufacturing systems and regulatory histories. Recombinant KLK1 is estimated to hold 56.1% of product type revenue in 2026, supported by higher development value and standardized composition. Preeclampsia is projected to represent 40.4% of indication revenue in 2026, attributable to recombinant research concentrated on maternal vascular dysfunction. Vasodilation and endothelial function is forecast to account for 64.4% of mechanism revenue in 2026, reflecting relevance across ischemic and hypertensive conditions. Marketed Asian products provide current access but cannot substitute for recombinant approval evidence across every formulation and national treatment pathway.
Geography and Growth Outlook	National outlooks separate countries with current kallidinogenase access from countries whose commercial value remains linked to investigational recombinant programs. Japan is projected to advance at 11.9% CAGR through 2036, supported by established product familiarity and a separate recombinant regulatory path. South Korea is forecast to expand at 11.2% CAGR over the forecast period, reflecting domestic oral product availability plus formulation-specific evidence requirements. Germany is estimated to post 8.8% CAGR during the assessment period, attributable to European evidence transfer and local reimbursement review. The USA and UK are anticipated to expand during the assessment period, enabled by clinical infrastructure but constrained by pending approval and commercialization requirements.
Competitive Landscape	Competition includes a recombinant developer and a product-specific manufacturing partner alongside Asian companies with authorized kallidinogenase preparations. DiaMedica Therapeutics controls DM199 clinical development and carries regulatory evidence responsibility across stroke and pregnancy programs. Catalent Pharma Solutions supports licensed expression and manufacturing technology without owning an approved KLK1 therapeutic brand. Guangdong Techpool Bio-Pharma combines production and commercialization for Kailikang within China’s acute ischemic stroke pathway. Japanese and South Korean manufacturers compete through current oral products whose formulation ownership determines national commercial access.
Analyst Perspective	Commercial value depends on whether each formulation connects defensible outcomes with reliable supply and a country-specific route to routine use. Active enrollment does not create an approved prescribing channel, so executives should separate clinical milestones from revenue. Manufacturing agreements require product-specific review because process control and intellectual property can determine later scale-up flexibility. Country entry plans should match formulation status and reimbursement evidence instead of relying on broad Asian precedent. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the tissue kallikrein 1 (KLK1) therapeutics market segmented?

The tissue kallikrein 1 (KLK1) therapeutics industry is segmented by product type, indication, mechanism, development stage, and region.

The product type category separates recombinant human KLK1 from native or extracted kallidinogenase preparations with different production controls. Indication analysis distinguishes maternal vascular disorders from acute ischemic stroke and chronic kidney disease plus hypertension and other uses. Mechanism analysis separates vasodilation and endothelial support from anti-inflammatory activity across the defined therapeutic pathway. Development stage divides products already marketed in Asian countries from recombinant programs in Western clinical development. Regional analysis compares approval status and distribution channels across countries with distinct product histories and care systems.

What supports demand for recombinant KLK1 within the product type category?

Recombinant KLK1 addresses consistency limitations that can accompany proteins extracted from human urine or animal pancreas. ClinicalTrials.gov reported on April 28, 2026 that ReMEDy2 remained recruiting across approximately 100 sites with enrollment permitted up to 728 participants. The multicountry design requires repeatable drug substance and coordinated site supply across participating hospitals and research networks. Standardized recombinant DNA platforms therefore influence blinded dosing and later manufacturing comparability across every study batch.

• Within product type, recombinant KLK1 is projected to account for 56.1% share in 2026 and is supported by consistent composition across multicenter programs. Its position also reflects higher development value than established oral kallidinogenase products serving narrower national channels.
• Biopharmaceutical sponsors evaluate recombinant KLK1 through endpoint quality and the feasibility of commercial scale-up across regulated markets. Biopharmaceutical outsourcing can reduce infrastructure requirements but adoption remains conditional on pivotal outcomes and national approval plus validated comparability across later registration batches.

How do maternal-fetal medicine centers evaluate preeclampsia therapies?

Preeclampsia programs need maternal blood-pressure control without creating unacceptable fetal exposure or disrupting urgent obstetric care. Treatment protocols also need rapid monitoring that fits delivery planning and escalation decisions across specialist maternity units. DiaMedica reported in July 2025 that interim Phase 2 data showed no placental transfer alongside statistically significant blood-pressure and uterine-artery responses. Obstetric teams require larger safety datasets and clear administration procedures before routine adoption across specialist maternity services.

• Preeclampsia is estimated to represent 40.4% of the indication category in 2026, reflecting an unmet disease-modifying treatment pathway. The estimated share also captures current recombinant development concentrated around pregnancy-related endothelial dysfunction and commercial valuation within specialist maternal care.
• Maternal-fetal medicine centers assess KLK1 therapy through fetal exposure and the ability to integrate dosing within delivery planning. Preterm birth management creates an additional constraint because treatment value declines without rapid monitoring and escalation across high-risk pregnancy units and referral networks.

Why is vasodilation and endothelial function central to the mechanism category?

Vasodilation and endothelial function connect KLK1 activity with local perfusion and vascular resistance across the target indications. DiaMedica’s March 2026 annual filing describes KLK1 as a serine protease that increases nitric oxide and prostacyclin plus endothelium-derived hyperpolarizing factor. The pathway connects biologic drug development with clinical outcome validation instead of treating biomarker movement as sufficient commercial evidence. Investigators must connect pathway activity with functional recovery or maternal stability before commercial decisions become defensible.

• Vasodilation and endothelial function is forecast to represent 64.4% of the mechanism category in 2026, attributable to relevance across blood-pressure control and ischemic perfusion. Anti-inflammatory action remains a supporting pathway rather than the primary treatment proposition within the approved market definition.
• Neurology and maternal-fetal medicine investigators require outcome measures that distinguish improved perfusion from transient physiological changes during treatment. Commercial acceptance depends on reproducible patient benefit and manageable dosing with safety evidence that remains credible across separate indications and specialist monitoring requirements.

How does marketed Asian availability shape the development stage category?

Marketed Asian preparations create prescription channels that differ substantially from the investigational Western route for recombinant DM199. National formularies and product-specific distributors determine routine access for oral or injectable kallidinogenase preparations across patient settings. Guangdong Techpool’s current corporate overview identifies Kailikang as a marketed injection supported by integrated research and production plus sales. Established therapeutic enzyme production supports current access but Japanese and South Korean oral formulations carry different labels and supply routes.

• By development stage, marketed Asia is likely to capture 56.5% share in 2026 and is enabled by product authorization plus existing prescriber access. The position reflects commercial availability across several Asian countries rather than equivalent regulatory acceptance for every formulation or indication.
• Hospital pharmacies and national distributors can purchase marketed preparations through current channels while recombinant entrants require separate local review. Adoption therefore depends on product-specific labeling and reliable manufacturing plus clinical acceptance rather than the general presence of kallidinogenase within a country.

What are the drivers, restraints, and opportunities in the tissue kallikrein 1 (KLK1) therapeutics market?

Multicenter clinical programs support demand for recombinant KLK1; incomplete approval and commercialization pathways restrain near-term access; established Asian channels create an opening for companies that connect evidence with reliable manufacturing.

• Driver: Acute ischemic stroke and preeclampsia programs create demand for therapies that address patients with limited disease-modifying treatment options.
• Restraint: Recombinant DM199 remains investigational and requires additional clinical evidence plus manufacturing development and national approval before routine prescribing.
• Opportunity: Product-specific manufacturing partnerships can connect standardized recombinant supply with multicountry trials and later commercial registration.

Large treatment gaps in vascular pregnancy disorders create a clear development pressure for recombinant KLK1 programs. DiaMedica announced in June 2026 that the first participants had received DM199 in a Phase 2 fetal growth restriction trial and stated that no pharmacologic treatment was approved for the condition. Specialist study coordination supports healthcare contract research capabilities that coordinate specialist centers and maternal monitoring across short treatment windows. Sponsors gain commercial value from broader enrollment only if final evidence demonstrates meaningful outcomes and manageable safety within ordinary care pathways.

Regulatory uncertainty remains one of the hurdles to market growth as no DM199 product has completed clinical development or received commercial approval. DiaMedica’s March 2026 annual filing states that commercial availability remains at least two to three years away and identifies further testing plus manufacturing development as necessary. Investors therefore carry timing risk across pivotal outcomes and regulatory review plus partner-led distribution and funding decisions. Development spending can expand but routine Western revenue remains unavailable until approval and commercial infrastructure are established.

Standardized supply creates a credible opening for recombinant KLK1 developers serving multicountry trials and later commercial batches. DiaMedica’s March 2026 filing confirms an exclusive Catalent license for methods and reagents used to produce DM199 or another human KLK1 protein. The relationship connects product-specific intellectual property with controlled active-substance production across clinical stages and registration batches. Commercial capture requires validated manufacturing and partner readiness plus country submissions that preserve consistent product quality across every intended indication.

Which country CAGRs are profiled in the tissue kallikrein 1 (KLK1) therapeutics market?

Country	CAGR
USA	7.8%
UK	7.4%
Germany	8.8%
Japan	11.9%
South Korea	11.2%

How do country-level CAGRs compare in the tissue kallikrein 1 (KLK1) therapeutics market?

The five-country profile spans 4.5 percentage points from 7.4% to 11.9% and creates two close pairs plus one intermediate position. Japan and South Korea form a 0.7-point East Asian cluster while the USA and UK sit 0.4 points apart. Germany stands 1.0 point above the USA and 2.4 points below South Korea. The spacing reflects different combinations of marketed-product access and trial participation plus regulatory preparation rather than one adoption curve. Similar percentages can conceal different revenue bases because marketed oral or urinary products do not carry the same development economics as recombinant programs.

• Japan’s position reflects established kallidinogenase access while recombinant entry would require a separate national registration and reimbursement pathway.
• South Korea remains close to Japan because domestic tablets create product familiarity but injectable recombinant adoption needs independent evidence and approval.
• Germany occupies the intermediate position through specialist research capacity alongside a later route for national reimbursement and distribution.
• The USA forms the lower cluster through a broad clinical network while routine commercial revenue remains unavailable without regulatory approval.
• The UK sits near the USA through NHS research access but national prescribing requires authorization and health-technology assessment.

Service coverage and reimbursement evidence alter entry budgets even across countries with similar forecast rates. Companies should compare legal status and clinical infrastructure separately from CAGR before assigning capital to national expansion. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States stroke centers can recruit DM199 participants through a large multicenter network but the product remains unavailable for routine prescribing. The tissue kallikrein 1 therapeutics market in the USA is projected to grow at 7.8% CAGR through 2036 and is supported by specialist stroke infrastructure. DiaMedica’s March 2026 annual filing describes active ReMEDy2 participation across the United States and other Western countries while confirming no commercial product revenue. Research capacity provides an adoption enabler but absent approval creates a reimbursement and distribution friction. Sponsors entering the USA must align stroke catheter workflows with non-thrombectomy eligibility criteria and define post-approval supply responsibility.
• United Kingdom investigators can evaluate DM199 within NHS research pathways that connect ethics review with specialist stroke centers. Demand for tissue kallikrein 1 therapeutics in the UK is anticipated to advance at 7.4% CAGR over the forecast period and is influenced by active research participation. National prescribing would still require marketing authorization and health-technology assessment through a formal national access pathway. The Health Research Authority record shows a favorable opinion dated August 28, 2025 for the Phase 2/3 ReMEDy2 study. Central review provides a direct enabler but national reimbursement remains a material friction for future prescribing. Developers need country-specific outcomes that explain which stroke patients receive DM199 outside existing intervention routes.
• German neurologic research centers support complex acute-stroke trials although the current ReMEDy2 European network does not include a German site. Germany’s tissue kallikrein 1 therapeutics outlook is estimated to post 8.8% CAGR between 2026 and 2036 and is attributable to specialist capacity plus a later entry route. The European Medicines Agency CTIS record accessed in July 2026 lists study locations in Belgium and France plus Spain and several Central European countries. Nearby trial activity enables evidence transfer but Germany lacks direct recruitment and an approved commercial product. Entry planning must address local clinical validation and reimbursement review plus biologic service coverage across stroke centers.
• Japanese prescribing channels include several kallidinogenase formulations but product continuity varies across manufacturer-specific regulatory records. Adoption of tissue kallikrein 1 therapeutics in Japan is forecast to expand at 11.9% CAGR through 2036 and is enabled by established product familiarity. PMDA product information published on June 19, 2026 classifies the 50-unit NIG kallidinogenase tablet as a former product and identifies separate manufacturing and selling entities. Existing therapeutic familiarity provides an enabler but retired product records create a material stocking and contracting friction. Recombinant DM199 would require formulation-specific registration plus reimbursement evidence and dependable distribution through Japanese medical institutions.
• South Korean manufacturers maintain prescription kallidinogenase tablets through domestic finished-dose channels and established circulatory-treatment portfolios. South Korea’s tissue kallikrein 1 therapeutics sector is projected to record 11.2% CAGR during the assessment period and is linked to available products plus local manufacturing. Dongsung Bio Pharm’s current product record accessed in July 2026 lists Kalimer tablets containing 50 IU of porcine-pancreas kallidinogenase for peripheral circulatory disorders. Domestic availability creates a direct enabler but animal-derived tablets cannot substitute for recombinant clinical evidence or new-indication approval. Companies need formulation-specific regulatory plans and hospital education plus pharmacovigilance arrangements for future injectable biologic adoption.

Who are the notable companies in the tissue kallikrein 1 (KLK1) therapeutics market?

DiaMedica Therapeutics; Catalent Pharma Solutions; Guangdong Techpool Bio-Pharma; Sanwa Kagaku Kenkyusho; Nichi-Iko Pharmaceutical; Unipharm Korea; Dongsung Bio Pharm; and Dae Hwa Pharmaceutical are notable companies in this market.

Competition separates clinical-stage recombinant development from marketed kallidinogenase products and product-specific manufacturing support within the defined market. DiaMedica owns the active DM199 clinical program while Catalent supplies licensed expression and manufacturing technology under the sponsor’s current filing. DiaMedica’s March 2026 annual report assigns regulatory evidence responsibility to the sponsor and active-substance production to Catalent. Guangdong Techpool operates Kailikang across research and production plus marketing in China under Shanghai Pharmaceuticals control. Japanese and South Korean companies compete through nationally available oral products with different legal owners and distribution routes. Commercial evaluation therefore requires current formulation responsibility and dependable access within the assessed geography and treatment pathway.

• DiaMedica Therapeutics controls clinical development and regulatory evidence for recombinant DM199 across acute ischemic stroke plus pregnancy programs. Catalent Pharma Solutions provides licensed expression and manufacturing support so sponsor selection depends on coordinated clinical supply with a credible path toward commercial-scale production.
• Guangdong Techpool Bio-Pharma markets Kailikang injection in China while Sanwa Kagaku Kenkyusho and Nichi-Iko Pharmaceutical maintain Japanese kallidinogenase products. Their commercial relevance comes from product-specific authorization and direct manufacturing responsibility within each national channel.
• Unipharm Korea and Dongsung Bio Pharm plus Dae Hwa Pharmaceutical list current 50 IU kallidinogenase tablets for circulatory indications in South Korea. Their portfolios demonstrate local finished-dose access although oral animal-derived products remain separate from recombinant DM199 development and approval.

Competitive Benchmarking: Tissue Kallikrein 1 (KLK1) Therapeutics Market

Company	Recombinant KLK1 Development	Marketed KLK1 Products	Manufacturing and Supply	Geographic Reach
DiaMedica Therapeutics	High	Low	Low	United States, Canada, UK and selected European trial markets
Catalent Pharma Solutions	Medium	Low	High	Global DM199 program
Guangdong Techpool Bio-Pharma	Low	High	High	China
Sanwa Kagaku Kenkyusho	Low	High	Medium	Japan
Nichi-Iko Pharmaceutical	Low	High	High	Japan
Unipharm Korea	Low	Medium	Medium	South Korea
Dongsung Bio Pharm	Low	Medium	Medium	South Korea
Dae Hwa Pharmaceutical	Low	Medium	Medium	South Korea

Scoring basis: Recombinant KLK1 Development rates High for an owned active clinical program and Medium for product-specific development or licensed manufacturing support. Low identifies an official exact-market offering limited to native or urinary kallidinogenase rather than recombinant development. Marketed KLK1 Products rates High for a current branded injectable or broad product family and Medium for a current national oral product. Low identifies an investigational role or manufacturing-support role that lacks an approved commercial KLK1 product within the defined boundary. Manufacturing and Supply rates High for direct exact-product production or integrated responsibility across regulated manufacturing and commercial release. Medium identifies documented marketing authorization or finished-dose support through a commercial manufacturing contract for a specific KLK1 product. Low identifies no owned production and reliance on a third party for active substance or finished product. Geographic Reach states countries supported by current products and trials plus manufacturing agreements without converting general corporate presence into market participation.

Key Developments in the Tissue Kallikrein 1 (KLK1) Therapeutics Market

• In March 2026, DiaMedica Therapeutics reported a Health Canada No Objection Letter supporting initiation of a Phase 2 DM199 study in early-onset preeclampsia. The planned study covers North American sites and a later United Kingdom expansion which creates a broader regulatory pathway for dose selection plus maternal safety evidence across regulated maternal-fetal medicine centers.
• In May 2026, DiaMedica Therapeutics: ReMEDy2 enrollment reached 75% of the 200-patient threshold required for the prespecified interim analysis. Approximately 70 sites were activated across the United States and Canada plus the United Kingdom and Europe which strengthened multicountry execution without changing DM199’s investigational status. The milestone reduced uncertainty around interim timing but did not establish efficacy or market authorization.
• In June 2026, Guangdong Techpool Bio-Pharma: Shanghai Pharmaceuticals confirmed that its member company continued integrated research and production plus marketing for Kailikang injection alongside other human-protein medicines. The update verifies current operating activity and full-chain product responsibility within China’s acute critical-care channel. China’s established distribution channel gives the company a direct commercial role that differs from Western clinical-stage participation.
• In January 2026, Sanwa Kagaku Kenkyusho: Japan’s PMDA published a revised package insert for Carnacrin 25-unit and 50-unit tablets plus the 25-unit capsule. The record names Sanwa as the marketing authorization holder and confirms current regulated documentation for native kallidinogenase products in Japan. The update supports ongoing product governance but does not establish recombinant DM199 approval or expansion into preeclampsia.

Key Players in the Tissue Kallikrein 1 (KLK1) Therapeutics Market

Clinical-Stage Recombinant Development and Manufacturing

• DiaMedica Therapeutics
• Catalent Pharma Solutions

Marketed KLK1 Providers in China and Japan

• Guangdong Techpool Bio-Pharma
• Sanwa Kagaku Kenkyusho
• Nichi-Iko Pharmaceutical

South Korean Kallidinogenase Providers

• Unipharm Korea
• Dongsung Bio Pharm
• Dae Hwa Pharmaceutical

Tissue Kallikrein 1 (KLK1) Therapeutics Market - Report Scope

Coverage field	Report scope
Market breakdown	Product type, indication, mechanism, development stage, and region.
Quantitative Units	USD million
Market Definition	Revenue from recombinant human KLK1 and marketed tissue kallikrein or kallidinogenase therapeutics used across approved or investigational vascular disease pathways.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea
Key Companies Profiled	DiaMedica Therapeutics, Catalent Pharma Solutions, Guangdong Techpool Bio-Pharma, Sanwa Kagaku Kenkyusho, Nichi-Iko Pharmaceutical, Unipharm Korea, Dongsung Bio Pharm, and Dae Hwa Pharmaceutical
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and official desk research.

Tissue Kallikrein 1 (KLK1) Therapeutics Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Tissue Kallikrein 1 (KLK1) Therapeutics Market by Segments

Tissue Kallikrein 1 (KLK1) Therapeutics Market segmented by Product Type:

• Recombinant KLK1 (DM199 / Rinvecalinase Alfa)
• Native/Urinary KLK1

Tissue Kallikrein 1 (KLK1) Therapeutics Market segmented by Indication:

• Preeclampsia
• Acute Ischemic Stroke
• Chronic Kidney Disease
• Hypertension
• Others

Tissue Kallikrein 1 (KLK1) Therapeutics Market segmented by Mechanism:

• Vasodilation & Endothelial Function
• Anti-inflammatory

Tissue Kallikrein 1 (KLK1) Therapeutics Market segmented by Development Stage:

• Marketed (Asia)
• Clinical Stage (West)

Tissue Kallikrein 1 (KLK1) Therapeutics Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• DiaMedica Therapeutics Inc. (2026, March 30). Annual report on Form 10-K for the fiscal year ended December 31, 2025.
• ClinicalTrials.gov. (2026, April 28). Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (NCT05065216).
• DiaMedica Therapeutics Inc. (2025, July 17). DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer.
• Guangdong Techpool Bio-Pharma Co., Ltd. (n.d.). Company overview.
• DiaMedica Therapeutics Inc. (2026, June 23). DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction.
• Health Research Authority. (2025, August 28). Study of DM199 for the treatment of Acute Ischemic Stroke.
• European Medicines Agency. (n.d.). A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke.
• Pharmaceuticals and Medical Devices Agency. (2026, January 26). [Carnacrin tablets 25 and 50 and Carnacrin capsule 25].
• Dongsung Bio Pharm Co., Ltd. (n.d.). Kalimer Tab.
• Dae Hwa Pharmaceutical Co., Ltd. (n.d.). [Karunadil tablet].
• Unipharm Korea Co., Ltd. (n.d.). KALLERSE Tablet (500Tab).
• DiaMedica Therapeutics Inc. (2026, March 30). DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights.
• DiaMedica Therapeutics Inc. (2026, May 20). DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial.
• Shanghai Pharmaceuticals Holding Co., Ltd. (2026, June 9). [Techpool: Deepening its focus on acute and critical care].
• Pharmaceuticals and Medical Devices Agency. (2026, June 19). [Kallidinogenase 50-unit tablet “NIG” (former product)].

This bibliography provides direct access to official records supporting the market analysis and current company information.

This Report Answers

• How large is the tissue kallikrein 1 (KLK1) therapeutics market in 2026 and 2036?
• What supports the 9.7% CAGR in the tissue kallikrein 1 (KLK1) therapeutics market?
• Why does recombinant KLK1 hold the largest product type share in 2026?
• How does preeclampsia influence clinical development and commercial planning for KLK1 therapeutics?
• How do country growth rates compare across the USA, UK, Germany, Japan, and South Korea?
• Which companies participate directly in the tissue kallikrein 1 (KLK1) therapeutics market?
• What limits routine adoption of recombinant DM199 across Western treatment pathways?
• How do marketed Asian products differ from investigational recombinant KLK1 programs?
• What evidence should decision-makers examine before funding clinical or commercial expansion?